Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline

2014; BioMed Central; Volume: 14; Issue: 1 Linguagem: Inglês

10.1186/1471-2334-14-391

1471-2334

Ana Carolina Campi‐Azevedo, Paula de Almeida Estevam, Jordana Grazziela Coelho-dos-Reis, Vanessa Peruhype-Magalhães, Gabriela Villela-Rezende, Patrícia Flávia Quaresma, Maria de Lourdes Sousa Maia, Roberto Farias, Luiz Antônio Bastos Camacho, Marcos da Silva Freire, Ricardo Galler, Anna M. Y. Yamamura, Luiz F.C. Almeida, Sheila Maria Barbosa de Lima, Rita Maria Ribeiro Nogueira, Glória Regina Silva e Sá, Darcy Akemi Hokama, Ricardo de Souza Carvalho, Ricardo Aguiar Villanova Freire, Edson Pereira Filho, M Leal, Akira Homma, Andréa Teixeira−Carvalho, Reinaldo de Menezes Martins, Olindo Assis Martins‐Filho,

Viral Infections and Vectors

The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine. Neutralizing antibody titers, viremia, cytokines and chemokines were tested on blood samples obtained from eligible primary vaccinees. The results demonstrated that a fifty-fold lower dose of 17DD-YF vaccine (587 IU) is able to trigger similar immunogenicity, as evidenced by significant titers of anti-YF PRNT. However, only subdoses as low as 3,013 IU elicit viremia kinetics with an early peak at five days after primary vaccination equivalent to the current dose (27,476 IU), while other subdoses show a distinct, lower in magnitude and later peak at day 6 post-vaccination. Although the subdose of 587 IU is able to trigger equivalent kinetics of IL-8/CXCL-8 and MCP-1/CCL-2, only the subdose of 3,013 IU is able to trigger similar kinetics of MIG/CXCL-9, pro-inflammatory (TNF, IFN-γ and IL-2) and modulatory cytokines (IL-5 and IL-10). The analysis of serum biomarkers IFN-γ and IL-10, in association to PRNT and viremia, support the recommendation of use of a ten-fold lower subdose (3,013 IU) of 17DD-YF vaccine.